FDA’s Lesko Says It Could Be Time to 'Rethink' Voluntary Genomic Submission Guidelines | GenomeWeb

PHILADELPHIA (GenomeWeb News) - With two years of experience under its belt, it may be time for the US Food and Drug Administration to "rethink" its Voluntary Genomic Submission Guidelines program, according to Larry Lesko, director of the Office of Clinical Pharmacology at FDA's Center for Drug Evaluation and Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.